BIOGEN INC. Available-for-sale Securities, Gross Unrealized Gain
BIOGEN INC. (BIIB) reported Available-for-sale Securities, Gross Unrealized Gain of $400.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2014-02-06
- BIOGEN INC. available-for-sale securities, gross unrealized gain for the quarter ending 2013-12-31 was $700.00K.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for the quarter ending 2013-09-30 was -$300.00K.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for the quarter ending 2011-03-31 was $1.80M.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for the quarter ending 2010-12-31 was -$1.80M.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for fiscal 2013 was $400.00K, a 92.86% decline from fiscal 2012.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for fiscal 2012 was $5.60M.
- BIOGEN INC. available-for-sale securities, gross unrealized gain for fiscal 2009 was $16.70M.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month | Available-for-sale Securities, Gross Unrealized Gain 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $400.00K derived: sum of 2 quarters · filed 2014-02-06 | $400.00K 10-K · filed 2014-02-06 | ||
| 2013-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$300.00K 10-Q · filed 2013-10-28 | |||
| 2013-06-30 | $0.00 10-Q · filed 2013-07-25 | ||||
| 2012-12-31 | $5.60M 10-K · filed 2014-02-06 | -$5.60M 10-Q · filed 2013-07-25 | |||
| 2011-03-31 | $1.80M 10-Q · filed 2011-04-21 | $0.00 derived: sum of 2 quarters · filed 2011-04-21 | -$3.20M derived: sum of 3 quarters · filed 2011-04-21 | ||
| 2010-12-31 | -$1.80M derived: 10-Q 12 month − 10-Q 9 month · filed 2011-04-21 | -$5.00M derived: sum of 2 quarters · filed 2011-04-21 | $3.50M 10-Q · filed 2011-04-21 | ||
| 2010-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $5.30M 10-Q · filed 2010-10-26 | |||
| 2010-06-30 | $8.50M 10-Q · filed 2010-07-20 | ||||
| 2009-12-31 | $16.70M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |